This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, ...

Lowering your “bad” cholesterol might be doing more than just protecting your heart, it could also be safeguarding your brain ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...

Though high cholesterol may contribute to the risk of developing Alzheimer’s disease or a related dementia (ADRD), taking a ...

CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...

Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease. The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...